EAN 2026 | EU approval of tolebrutinib marks new era in progressive multiple sclerosis

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, comments on the recent approval of tolebrutinib in the EU for the treatment of multiple sclerosis (MS) for secondary progressive multiple sclerosis without relapses. Dr Oreja-Guevara highlights the impact of this approval, which is the first treatment targeting disease progression. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.